相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
Christina Krupka et al.
BLOOD (2014)
Targeting T cells to tumor cells using bispecific antibodies
Stanley R. Frankel et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2013)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer
Jin Hyun Park et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
Dirk Nagorsen et al.
EXPERIMENTAL CELL RESEARCH (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia
R. Handgretinger et al.
LEUKEMIA (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody
T. Osada et al.
BRITISH JOURNAL OF CANCER (2010)
New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Hans Prenen et al.
CLINICAL CANCER RESEARCH (2010)
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression
Theresa L. Whiteside
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Activation of Signal Pathways and the Resistance to Anti-EGFR Treatment in Colorectal Cancer
Jiezhong Chen et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Immune infiltration in human tumors: a prognostic factor that should not be ignored
F. Pages et al.
ONCOGENE (2010)
Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells
Ines Herrmann et al.
PLOS ONE (2010)
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
Ralf Lutterbuese et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110
Juliane Witthauer et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
A. Oden-Gangloff et al.
BRITISH JOURNAL OF CANCER (2009)
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
J. Souglakos et al.
BRITISH JOURNAL OF CANCER (2009)
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies
Andrea Sartore-Bianchi et al.
CANCER RESEARCH (2009)
Bispecific T-Cell Engaging Antibodies for Cancer Therapy
Patrick A. Baeuerle et al.
CANCER RESEARCH (2009)
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer
Hans Prenen et al.
CLINICAL CANCER RESEARCH (2009)
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Cornelia Haas et al.
IMMUNOBIOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Antitumor Activity of an EpCAM/CD3-bispecific BiTE Antibody During Long-term Treatment of Mice in the Absence of T-cell Anergy and Sustained Cytokine Release
Maria Amann et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA
Ralf Lutterbuese et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Nicola Normanno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Minaxi Jhawer et al.
CANCER RESEARCH (2008)
BiTE: a new class of antibodies that recruit T-cells
P. A. Baeuerle et al.
DRUGS OF THE FUTURE (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab
Astrid Lievre et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Inflammatory cell infiltration of tumors: Jekyll or Hyde
James E. Talmadge et al.
CANCER AND METASTASIS REVIEWS (2007)
The genomic landscapes of human breast and colorectal cancers
Laura D. Wood et al.
SCIENCE (2007)
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
Klaus Brischwein et al.
JOURNAL OF IMMUNOTHERAPY (2007)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct
Scott A. Hammond et al.
CANCER RESEARCH (2007)
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
Silvia Benvenuti et al.
CANCER RESEARCH (2007)
CD19/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis
Michael Molhoj et al.
MOLECULAR IMMUNOLOGY (2007)
Carcinoembryonic antigen monitoring for early detection of asymptomatic incurable metastatic colorectal cancer
Mark Rother
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hyperactive Ras in developmental disorders and cancer
Suzanne Schubbert et al.
NATURE REVIEWS CANCER (2007)
Free DNA and carcinoembryonic antigen serum levels: An important combination for diagnosis of colorectal cancer
Emanuela Flamini et al.
CLINICAL CANCER RESEARCH (2006)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
Gershon Y. Locker et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
K Brischwein et al.
MOLECULAR IMMUNOLOGY (2006)
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
S Offner et al.
MOLECULAR IMMUNOLOGY (2006)
The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation:: Influence of tumor site, type of mutation, and adjuvant treatment
A Russo et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
BiTEs: bispecific antibody constructs with unique anti-tumor activity
E Wolf et al.
DRUG DISCOVERY TODAY (2005)
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
P Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
The development of a modified human IFN-α2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection
TD Jones et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2004)
A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours
RJ Francis et al.
BRITISH JOURNAL OF CANCER (2002)
被撤回的出版物: Radioimmunotherapy of small-volume disease of metastatic colorectal cancer -: Results of a phase II trial with the iodine-131-labeled humanized anti-carcinoembryonic antigen antibody hMN-14 (Retracted article. See vol. 121, pg. 2290, 2015)
TM Behr et al.
CANCER (2002)
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma
C Lavarino et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Immunohistochemical analysis of drug resistance-associated proteins in ovarian carcinomas
D Mayr et al.
PATHOLOGY RESEARCH AND PRACTICE (2000)
分享论文
